Skip Navigation

Trilantic North America Makes Strategic Growth Investment in SOFIE Biosciences

Trilantic North America announced today that it has entered into a definitive agreement to make a substantial growth investment in SOFIE Biosciences (“SOFIE” or the “Company”), a Positron Emission Tomography (“PET”) radiopharmacy and contract development and manufacturing organization (“CDMO”). The investment is being made in partnership with SOFIE’s founding team, who will retain a meaningful equity stake and continue to lead the business. The transaction is expected to close later this year, subject to customary closing conditions and regulatory approvals.

William Blair & Company, LLC acted as financial advisor and Kirkland & Ellis LLP provided legal advice to Trilantic North America. Solomon Partners Securities LLC acted as financial advisor and Paul, Weiss, Rifkind, Wharton & Garrison provided legal services to SOFIE Biosciences.

Jan 28, 2024

Trilantic Capital Management L.P. (“Trilantic North America”) is a growth-focused middle market private equity firm focused on control and significant minority investments in North America. Trilantic North America’s primary investment focus is in the business services and consumer sectors. Trilantic North America has managed or is currently managing seven private equity fund families with aggregate capital commitments of $10.9 billion.

About Trilantic North America

SOFIE's vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services and high value theranostic intellectual property, SOFIE is poised to deliver on the promise of radiopharmaceuticals. For more information, visit or contact us by email at

About SOFIE Biosciences